Chemoimmunotherapy of MC-induced mouse sarcomas with human recombinant interleukin 2 and cyclophosphamide: age-dependent decline of the therapeutic efficacy
Jazyk angličtina Země Česko Médium print
Typ dokumentu časopisecké články
PubMed
2789150
Knihovny.cz E-zdroje
- MeSH
- cyklofosfamid terapeutické užití MeSH
- experimentální sarkom chemicky indukované farmakoterapie MeSH
- imunoterapie MeSH
- interleukin-2 terapeutické užití MeSH
- lidé MeSH
- methylcholanthren MeSH
- myši inbrední C57BL MeSH
- myši MeSH
- rekombinantní proteiny terapeutické užití MeSH
- stárnutí * MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- myši MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- Názvy látek
- cyklofosfamid MeSH
- interleukin-2 MeSH
- methylcholanthren MeSH
- rekombinantní proteiny MeSH
Age-dependent decline of the anti-tumour efficacy of local IL-2 immunotherapy and chemoimmunotherapy utilizing human recombinant interleukin 2 and cyclophosphamide was investigated in B10 mice bearing syngeneic MC-induced sarcoma. Repeated peritumoral injections of rIL-2 substantially inhibited growth of transplantable MC-induced sarcomas in syngeneic young adult mice whereas no effect was observed in the aged mice. Chemoimmunotherapy of the MC-induced sarcomas in the young adult and in the aged mice treated with cyclophosphamide plus rIL-2 revealed that subthreshold doses of CY were capable of significantly potentiating the immunotherapeutic effect of rIL-2 in young adult mice but not in the aged mice.
Local and regional immunotherapy of cancer with interleukin 2
